EN
Multiplex Fluorescence PCR; CE-IVD；NMPA
K-ras Gene Mutations Detection Kit
Selecting patients for treatment of locally advanced or metastatic NSCLC with G12C inhibitor based on the presence of KRAS G12C ;
Selecting patients for treatment of metastatic colorectal cancer with anti-EGFR or anti-HER2 therapy based on the presence of KRAS.
KRAS MUTATIONS IN LUNG CANCER
Kirsten rat sarcoma viral oncogene (K-ras) is the most frequently mutated gene in patients with non-small cell lung cancer (NSCLC) in USA/Europe and the second most frequently mutated gene in patients with NSCLC in East Asian, with a mutation frequency of 9.8%; about 30% of which are G12C mutations [1]. K-ras mutation is associated with poor prognosis (compared to wild type, HR=1.5, P=0.002) [1]. In May 2021, the FDA approved AMGEN's KRAS G12C inhibitor Sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy.
KRAS MUTATIONS IN COLORECTAL CANCER
Cetuximab and panitumumab are monoclonal antibody drugs that target epidermal growth factor receptor (EGFR), which can competitively prevent EGFR from binding to its ligand and inhibit its downstream signal transmission. K-ras is located in the MAPK signaling pathway downstream of EGFR. The mutant K-ras protein does not depend on the regulation of EGFR, therefore， patients are resistant to cetuximab and panitumumab. The FDA specifically stated in the product instructions for cetuximab and Panitumumab that these drugs are not recommended for colorectal cancer patients with K-ras mutation.
DETECTED GENES
PRODUCT INFORMATION
Project Name
Core Technology
Pack Size
Instruments Validated
Sample Type
K-ras Gene Mutations Detection Kit
PAP-ARMS®
10 Tests/Kit
ABI7500,ABI7300,ABI StepOne Plus,LightCycler480,Bio-Rad CFX96, etc.
Tumor tissue Peripheral blood Pleural &Ascites
DETECTION SIGNIFICANCE
Select patients for treatment of locally advanced or metastatic NSCLC with G12C inhibitor based on the presence of KRAS G12C
mutation in tumor or plasma specimens.
Patients with mutant KRAS gene show poor response to anti-EGFR or anti-HER2 therapies.
FEATURES & ADVANTAGES
Accuracy and Reliability
Use pre-load PCR tube to effectively avoid cross-contamination
High Sensitivity
Sensitivity can reach as low as 1% in 10 ng DNA
Ease of Use
Based on technology PAP-ARMS, one step detection in 90 mins
Great versatility
Validated on the most common qPCR machines with stable results
DETECTION PROCESS
1. Nucleic acid extraction
2. Set up qPCR
3. Amplification
4.Data analysis
Popular Products
闽公网安备35021202000745